Investing in value stocks can pay off. By putting money into companies that are trading below what they’re actually worth, one can potentially generate healthy profits over the long term. Here, I’m going to highlight two FTSE 100 value stocks that I believe are worth a closer look right now. I’m convinced these shares deserve to be trading at higher levels.
This Footsie giant looks undervalued
First up is pharma giant GSK (LSE: GSK).
GSK shares have fallen over the last year and I think they offer a lot of value today. At present, the company’s forward-looking price-to-earnings ratio (P/E) is just 10.4. That’s a low multiple.
To put that figure in perspective, rival AstraZeneca currently has a P/E ratio of about 20. Meanwhile, the median P/E ratio across the FTSE 100 index is about 14.
GSK’s recent performance has been solid. Last year, sales were up 13% at constant currency to £29.3bn. Meanwhile, adjusted earnings per share were up 15% to 139.7p.
However, what’s spooking investors here is potential Zantac litigation (Zantac was withdrawn from shelves in 2019 after being linked to cancer). This is creating some uncertainty.
I’m encouraged by a recent statement from the pharma giant, however. It said that the scientific consensus across 13 epidemiological studies focused on the product was that there was “no consistent or reliable evidence” that it increases the risk of any cancer.
So, all things considered, I see the stock as undervalued right now.
Trading at a discount to the market
The other value stock I want to highlight today is DS Smith (LSE: SMDS). It’s a sustainable packaging company that serves customers in the e-commerce and food industries.
Like GSK, DS Smith trades at a discount to the market. Currently, the company is expected to generate earnings per share of 42.9p for the year ending 30 April 2023. That puts the stock on a forward-looking P/E ratio of just 7.5.
That seems too low to me.
In a trading update last month, DS Smith told investors that the positive trends in profitability experienced in the first half of the financial year had continued into the second half.
It added that it was positioned well for the remainder of the year and next year.
It’s worth noting here that in the company’s H1 results, it raised its dividend by a huge 25%. That suggests management is confident about the future.
The prospective dividend yield here, by the way, is currently about 5.8%. That’s attractive.
Of course, packaging is a ‘cyclical’ industry. So weak economic conditions are a risk in the short term.
But taking a long-term view, I expect this company to do well. In the years ahead, it should enjoy tailwinds from both the growth of e-commerce and the increasing focus on sustainability.
The post 2 FTSE 100 value stocks to look at NOW appeared first on The Motley Fool UK.
Should you buy Gsk shares today?
Before you decide, please take a moment to review this first.
Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.
It’s called ‘5 Stocks for Trying to Build Wealth After 50’.
And it’s yours, free.
Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.
And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.
That’s why now could be an ideal time to secure this valuable investment research.
Mark’s ‘Foolish’ analysts have scoured the markets low and high.
This special report reveals 5 of his favourite long-term ‘Buys’.
Please, don’t make any big decisions before seeing them.
Claim your free copy now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
Best British value stocks to buy in April
Aim for £1,000 passive income buying 40 shares of this FTSE 100 stock a week
Here’s the GSK dividend forecast for 2023 and 2024
Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has recommended DS Smith and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.